MedTrace Logo

Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization

NCT03455309 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 382

Last updated 2020-01-29

No results posted yet for this study

Summary

The proposed study aims to further evaluate the safety and immunogenicity of a candidate S. aureus vaccine NDV-3A, as well as its efficacy against acquisition of S. aureus

Conditions

  • Staphylococcus Aureus

Interventions

BIOLOGICAL

NDV-3A

Single dose administered by intramuscular injection

BIOLOGICAL

Placebo

Single dose administered by intramuscular injection

Sponsors & Collaborators

  • Infectious Diseases Clinical Research Program

    collaborator OTHER

  • Uniformed Services University of the Health Sciences

    collaborator FED

  • NovaDigm Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Jason W Bennett, MD · USU IDCRP

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
17 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-30
Primary Completion
2019-07-19
Completion
2019-10-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03455309 on ClinicalTrials.gov